tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Hernández D et al. | Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. | 2007 | Transplantation | pmid:17893603 |
| Connor A et al. | Generic tacrolimus in renal transplantation: trough blood concentration as a surrogate for drug exposure. | 2012 | Transplantation | pmid:23318306 |
| Plock JA et al. | Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells Prolong Graft Survival in Vascularized Composite Allotransplantation. | 2015 | Transplantation | pmid:26102613 |
| Gurk-Turner C et al. | Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. | 2008 | Transplantation | pmid:18497682 |
| Khanafer A et al. | Increased nitric oxide production during acute rejection in kidney transplantation: a useful marker to aid in the diagnosis of rejection. | 2007 | Transplantation | pmid:17876269 |
| Singh N et al. | Immunosuppressive-associated leukoencephalopathy in organ transplant recipients. | 2000 | Transplantation | pmid:10708096 |
| Haririan A et al. | Polyomavirus reactivation in native kidneys of pancreas alone allograft recipients. | 2003 | Transplantation | pmid:12717201 |
| Gonwa T et al. | Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. | 2003 | Transplantation | pmid:12717205 |
| Taber DJ et al. | Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. | 2017 | Transplantation | pmid:28658199 |
| Diémé B et al. | Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling. | 2014 | Transplantation | pmid:24598938 |
| Kim CD et al. | Metabonomic analysis of serum metabolites in kidney transplant recipients with cyclosporine A- or tacrolimus-based immunosuppression. | 2010 | Transplantation | pmid:20842074 |
| Stegall MD et al. | Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. | 1997 | Transplantation | pmid:9422404 |
| Shield CF et al. | Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression. FK506 Kidney Transplant Study Group. | 1997 | Transplantation | pmid:9422413 |
| Murase N et al. | Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. | 1990 | Transplantation | pmid:1696405 |
| Demetris AJ et al. | Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. | 1992 | Transplantation | pmid:1374944 |
| Demmers MW et al. | Limited efficacy of immunosuppressive drugs on CD8+ T cell-mediated and natural killer cell-mediated lysis of human renal tubular epithelial cells. | 2014 | Transplantation | pmid:24704664 |
| Shibutani S et al. | Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. | 2005 | Transplantation | pmid:15849542 |
| Tory R et al. | Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. | 2009 | Transplantation | pmid:19584682 |
| Manitpisitkul W et al. | Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. | 2009 | Transplantation | pmid:19584685 |
| Weiler N et al. | Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. | 2010 | Transplantation | pmid:21048536 |
| Chisholm MA et al. | Renal transplant patient compliance with free immunosuppressive medications. | 2000 | Transplantation | pmid:11063348 |
| Dominguez J et al. | Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. | 2000 | Transplantation | pmid:11063349 |
| Busuttil RW et al. | General guidelines for the use of tacrolimus in adult liver transplant patients. | 1996 | Transplantation | pmid:8607197 |
| Esquivel CO et al. | Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. | 1996 | Transplantation | pmid:8607198 |
| Barraclough KA et al. | NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation. | 2012 | Transplantation | pmid:23095803 |
| Nogueira JM et al. | A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. | 1999 | Transplantation | pmid:10096529 |
| Hoogduijn MJ et al. | Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. | 2008 | Transplantation | pmid:19005411 |
| Tzakis AG et al. | Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. | 2004 | Transplantation | pmid:15114087 |
| Bechstein WO et al. | Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. | 2004 | Transplantation | pmid:15114089 |
| Serón D et al. | Immunophenotype of infiltrating cells in protocol renal allograft biopsies from tacrolimus-versus cyclosporine-treated patients. | 2007 | Transplantation | pmid:17353788 |
| Talbot D et al. | Alopecia as a consequence of tacrolimus therapy in renal transplantation? | 1997 | Transplantation | pmid:9415574 |
| Gregory CR et al. | Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. | 1995 | Transplantation | pmid:7533955 |
| Wallia A et al. | Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. | 2010 | Transplantation | pmid:20098286 |
| Vossen M et al. | Bone quality in swine composite tissue allografts: effects of combination immunotherapy. | 2005 | Transplantation | pmid:16123723 |
| Suzuki S et al. | Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. | 1993 | Transplantation | pmid:7685932 |
| Qi S et al. | Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. | 2000 | Transplantation | pmid:10798741 |
| McDiarmid SV et al. | Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. | 1993 | Transplantation | pmid:7685933 |
| Lauria MW et al. | Metabolic long-term follow-up of functioning simultaneous pancreas-kidney transplantation versus pancreas transplantation alone: insights and limitations. | 2010 | Transplantation | pmid:20061923 |
| Gullestad L et al. | Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. | 2010 | Transplantation | pmid:20061999 |
| Pascual M et al. | Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. | 1998 | Transplantation | pmid:9869086 |
| Ciancio G et al. | Review of major clinical trials with mycophenolate mofetil in renal transplantation. | 2005 | Transplantation | pmid:16251852 |
| Strumph P et al. | The effect of FK506 on glycemic response as assessed by the hyperglycemic clamp technique. | 1995 | Transplantation | pmid:7542815 |
| Baran DA et al. | Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol. | 2002 | Transplantation | pmid:12438960 |
| Kasahara M et al. | Role of HLA compatibility in pediatric living-related liver transplantation. | 2002 | Transplantation | pmid:12438966 |
| Hudnall SD | Cardiac hypertrophy postliver transplantation: a role for FK506 and cyclosporine A? | 2002 | Transplantation | pmid:12369583 |
| de Jonge H et al. | Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. | 2010 | Transplantation | pmid:20592652 |
| Shibasaki S et al. | Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway. | 2013 | Transplantation | pmid:23269193 |
| Yuzawa K and Fukao K | Topical FK506 ointment for skin grafting. | 1998 | Transplantation | pmid:9565111 |
| Puig I Marà JM et al. | Reflex sympathetic dystrophy syndrome of the lower limbs in a renal transplant patient treated with tacrolimus. | 2000 | Transplantation | pmid:10919604 |
| Erickson LM et al. | Microarray-based gene expression profiles of allograft rejection and immunosuppression in the rat heart transplantation model. | 2003 | Transplantation | pmid:12923448 |